Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    GTNF 2023: SMOORE Takes Home the Golden Leaf Award and Presents Framework for Innovating Through Industry Challenges

    September 25, 2023

    AIST to Hold 5th RD20 Conference on Oct. 4-6 in Fukushima, Renewable Energy Frontier

    September 25, 2023

    Campus With A Conscience hosts a week-long UN festival

    September 25, 2023
    Facebook X (Twitter) Instagram
    KSA News HubKSA News Hub
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    KSA News HubKSA News Hub
    Home » MedAlliance Enrolls First US Patient into its Third FDA IDE Study: SFA SELUTION4SFA
    PR Newswire

    MedAlliance Enrolls First US Patient into its Third FDA IDE Study: SFA SELUTION4SFA

    May 5, 2023
    Facebook Twitter Pinterest LinkedIn Reddit WhatsApp Email

    GENEVA, May 5, 2023 /PRNewswire/ — The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr. Arthur Lee at the Cardiac & Vascular Institute in Florida. This study evaluates SELUTION SLR™ in the treatment of occlusive disease of the superficial femoral artery (SFA) and proximal popliteal artery (PPA) and has been designed to support FDA approval. It follows Investigational Device Exemption (IDE) approval in the US in August 2022. SELUTION SLR is the first and only limus release drug-eluting balloon (DEB) to receive FDA IDE approval for SFA and PPA indications.

    MedAlliance Enrolls First US Patient into its Third FDA IDE Study: SFA SELUTION4SFA

    SELUTION4SFA is being conducted in over 30 centers in the US plus an additional 10 centers worldwide. The study will enroll 300 patients, with the aim of demonstrating the superiority of SELUTION SLR over balloon angioplasty (POBA). The primary efficacy endpoint is primary patency of the target lesion at 12 months and the primary safety endpoint is freedom from death at 30 days. Enrollment into the study will be complete by the end of 2023.

    “We are excited to introduce the first Sirolimus DEB to US patients, and look forward to a rapid enrollment of this important study,” commented Dr. Jay Mathews, Co-Principal Investigator, Manatee Memorial Hospital, Bradenton, Florida. “We hope to learn how this technology can potentially benefit patients with complex peripheral arterial disease.”

    “We are pleased to be enrolling our third IDE study in US patients, and look forward to the results of these three studies as well as future IDE studies to come,” added Jeffrey B. Jump, Chairman and CEO of MedAlliance.

    SELUTION SLR was awarded CE Mark Approval for the treatment of coronary artery disease in May 2020. MedAlliance was the first drug-eluting balloon company to receive FDA Breakthrough Designation status. Currently, three IDE clinical studies are evaluating SELUTION SLR in the US: in CLTI patients with BTK disease; SFA/PPA; and coronary ISR. In addition, MedAlliance received IDE approval for de novo coronary artery lesions in January 2023. This complements the substantial experience that the company has gained with the SELUTION DeNovo and SUCCESS trials in Europe.

    MedAlliance’s unique DEB technology involves MicroReservoirs which contain a combination of biodegradable polymer intermixed with the anti-restenotic drug sirolimus, applied as a coating on the surface of an angioplasty balloon. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days. MedAlliance’s proprietary CAT™ (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and efficiently transferred to adhere to the vessel lumen when delivered via expansion of the balloon.

    SELUTION SLR is commercially available in Europe, Asia, the Middle East, and the Americas (outside USA) and most other countries where the CE Mark is recognized. Over 10,000 units have been used for patient treatments in routine clinical practice or as part of coronary clinical trials. Please contact us if your centre is interested in participating in this study.

    About MedAlliance

    MedAlliance is medical technology company which announced a staged acquisition by Cordis in October 2022. It is headquartered in Nyon, Switzerland. MedAlliance specializes in the development of ground-breaking technology and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery disease. For further information, visit: www.medalliance.com

    Media Contact:
    Richard Kenyon
    rkenyon@medalliance.com
    +44 7831 569940

    Photo: https://mma.prnewswire.com/media/2069598/MedAlliance_SLR_DEB.jpg
    Logo: https://mma.prnewswire.com/media/1196864/MedAlliance_Logo.jpg

    MedAlliance Logo

    Cision View original content:https://www.prnewswire.com/ae/news-releases/medalliance-enrolls-first-us-patient-into-its-third-fda-ide-study-sfa-selution4sfa-301815844.html

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email

    Related Posts

    GTNF 2023: SMOORE Takes Home the Golden Leaf Award and Presents Framework for Innovating Through Industry Challenges

    September 25, 2023

    AIST to Hold 5th RD20 Conference on Oct. 4-6 in Fukushima, Renewable Energy Frontier

    September 25, 2023

    Campus With A Conscience hosts a week-long UN festival

    September 25, 2023

    Artmarket.com: France obtains the maintenance of VAT at the reduced rate of 5.5% on the Art Market, a major victory with very considerable advantages according to Artprice.

    September 25, 2023

    GET THAT ‘CAN’T WAIT TO WINTER’ FEELING IN ABU DHABI

    September 25, 2023

    Huawei Accelerates the Commercial Market Advancement and Helps SMEs Go Digital and Intelligent

    September 25, 2023
    Latest News
    Business

    From India to Brazil, leadership transition marks G20 Summit’s conclusion

    September 11, 2023

    At the Bharat Mandapam in New Delhi, the curtains have come down on the 18th…

    African Union Inducted into G20 on India’s Initiative

    September 9, 2023

    Biden and Modi cement ties as India ascends global stage

    September 9, 2023

    UN calls for greater female representation in police forces worldwide

    September 8, 2023

    Digital work revolution sees the world’s gig economy expand by 12 percent

    September 8, 2023

    AI drives MENA Newswire’s entry into Saudi digital media

    September 8, 2023

    ASEAN Summit in Jakarta sees PM Modi advocating India’s growing global impact

    September 7, 2023

    Air Canada faces backlash as passengers evicted for refusing vomit-soaked seating

    September 7, 2023
    © 2021 KSA News Hub | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.